AstraZeneca Goes Deeper Into China Cardiovascular Focus With Tianjin Medical University Agreement
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca has signed a collaboration agreement with Chinese research institution Tianjin Medical University to co-explore novel targets against cardiac fibrosis. The agreement builds on a string of such academic collaborations in the country focused on growing chronic diseases.